Medscape is available in 5 Language Editions – Choose your Edition here.


Social Phobia Treatment & Management

  • Author: Bettina E Bernstein, DO; Chief Editor: Eduardo Dunayevich, MD  more...
Updated: Jan 12, 2016

Approach Considerations

A combination of pharmacotherapy and psychotherapy is usually indicated for persons with social phobia.


Medical Care


Antidepressants including selective serotonin reuptake inhibitors (SSRIs; citalopram [Celexa], escitalopram [Lexapro], fluvoxamine [Luvox], paroxetine [Paxil], fluoxetine [Prozac], sertraline [Zoloft]) and venlafaxine (Effexor) are commonly prescribed to treat the symptoms of social phobia and generally result in remission of symptoms after 4 weeks of treatment. However, it is important to balance benefits and the potential for adverse effects when prescribing medications.[40, 41, 4, 42]

  • SSRIs: SSRIs are quickly becoming the standard first-line medication for social phobia. Paroxetine received US Food and Drug Administration (FDA) approval for this indication in 1999, the first SSRI to gain such approval. In 2003, sertraline received FDA approval for short- and long-term (20-wk) treatment of social phobia in adults. It is also FDA-approved for the treatment of obsessive-compulsive disorder (OCD) in children older 12 years.
  • Serotonin norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine, were approved for the treatment of social phobia in 2003 for use in adults but may not be as effective or safe in children. Studies suggest that other SSRIs may also be effective. However, the FDA recommends caution when using these agents to treat social phobia in children younger than 18 years because of concerns about the potential increased risk of newly onset suicidal ideation, especially with venlafaxine and paroxetine. Nonetheless, numerous open and controlled studies support the efficacy of SSRIs/SNRIs in this population as part of a multimodal approach, with close monitoring of mental status. [43, 44, 41, 4]
  • Benzodiazepines: Benzodiazepines may be effective for social phobia but are generally undesirable in the absence of contraindications to SSRI use. Alprazolam and clonazepam have been used successfully for this indication, but all agents in this class, although very helpful in comorbid panic, should not be used for longer than 6 weeks because of the risk of increased depression and physical dependence. [41, 4]
  • Buspirone: Some studies suggest efficacy in persons with social phobia and less of a risk of physical dependence than is commonly seen with benzodiazepines. However, it has not been FDA-approved for the treatment of anxiety disorders in children. [41, 4]
  • Gabapentin: Recent studies suggest the efficacy of gabapentin for this indication; however, it is not FDA-approved for use in social phobia in adults or children. [44, 4]
  • Propranolol: Beta-blockers have been used to block the autonomic response in persons with social phobia. Preventing symptoms such as tremor and increased heart rate may lead to successful performance in social situations despite anxiety. However, propranolol should not be used in persons with asthma or in combination with other antihypertensive agents. This medication is not yet FDA-approved for use in children. [4]
  • Clonidine (alpha-adrenergic blocker) may work to block the autonomic response in persons with social phobia, similarly to the effect conferred by propranolol, and can be particularly useful in persons with comorbid posttraumatic stress disorder or acute stress reactions. [4]
  • Monoamine oxidase inhibitors (MAOIs): These agents are not approved for use in children, but they are FDA-approved for use in adults for unipolar depression. Phenelzine has been demonstrated to be effective in controlled studies. The dietary restrictions required when taking MAOIs reduces their popularity. Moclobemide, a newer reversible MAOI, has shown some efficacy in persons with social phobia. Selegiline (EmSam, a patch) may be superior to other agents in this class because of a slightly decreased risk of serotonin syndrome if used in the lowest dosage range. [4]
  • D-cycloserine: This medication has not yet been proven effective for the treatment of social phobia, but studies are ongoing. [45, 4]


Cognitive restructuring can be combined with in vivo exposure, performance feedback, and attention retraining and/or combined with nonspecific stress management or computer-based cognitive behavior therapy (CBT).[46]

Cognitive therapy has evidence-based efficacy.[47, 48]

A study of adults was a randomized controlled trial of 117 persons undergoing social anxiety disorder (SAD) treatment who received 16 individual sessions of either cognitive therapy (CT) or interpersonal therapy (IPT) and 1 booster session.

Twenty weeks after randomization, a posttreatment assessment was conducted using the Clinical Global Impression Improvement Scale, as assessed by independent, masked evaluators, and a secondary outcome measures was conducted independent of assessor ratings using the Liebowitz Social Anxiety Scale, the Hamilton Rating Scale for Depression, and patient self-ratings of SAD symptoms.

At the posttreatment assessment, response rates were 65.8% for CT, 42.1% for IPT, and 7.3% for WLC (Wait List Control). Regarding response rates and Liebowitz Social Anxiety Scale scores, CT performed significantly better than IPT, and both treatments were superior to WLC. At 1-year follow-up, the differences between CT and IPT were largely maintained, with significantly higher response rates in the CT versus the IPT group (68.4% vs 31.6%) and better outcomes on the Liebowitz Social Anxiety Scale.

CT and IPT led to considerable improvements that were maintained 1 year after treatment; CT was more efficacious than IPT in reducing social phobia symptoms.

Adolescents, particularly school-refusing adolescents, improve with the use of CT, especially when developmentally sensitive, and when this therapy is performed in an inpatient setting. This may be related to the improvement of automatic thoughts and cognitive errors with the use of CBT.[49, 50]

Behavioral psychotherapies, such as gradual desensitization, are effective in persons with social phobia. This technique involves gradually exposing the patient to simulated situations that normally cause anxiety in the patient. By mastering the situation without anxiety, the patient is eventually able to tolerate more situations that previously induced anxiety.[24]

Specific CBTs that have been found to be effective include computerized CBT (several types including "Coping Cat") and clinician-assisted computerized CBT (CaCCBT). Studies have shown that cognitive restructuring needs to include a component of in vivo exposure with attention retraining and performance feedback. As CBT interventions for social phobia tend not to generalize, it is important to design interventions specific to social phobia. Computer-based interventions have the advantage of eliminating scheduling problems, as they are convenient, potentially more sensitive to cross-cultural issues, appealing to children and adults, and more easily affordable.[23, 24, 26]

Cognitive and insight-oriented therapies have proved useful in treating social phobia. Individuals with social phobia often have significant cognitive distortions related to what other people could be thinking about them that might respond to restructuring.[24]

Stress management and relaxation techniques such as biofeedback, meditation, and deep breathing can lessen anxiety but are not sufficient alone in the treatment of social phobia.[41]

Group psychodynamic psychotherapy and individual psychoanalytic psychotherapy (an approach used for many years in the treatment of phobias) are approaches that are especially effective if combined with pharmacotherapy such as anxiolytics.[42, 51, 52]

A 2013 randomized control trial found that predictors of a less favorable treatment response include anticipatory worry, rumination, and harm-avoidant personality traits.[53]

A 2015 multisite study, The Genes for Treatment Study (GxT), sampled data from 1,519 children who received a course of CBT for anxiety at 1 of 11 sites: Sydney, Australia; Reading, UK; Aarhus, Denmar; Bergen, Norway; Bochum, Germany; Basel, Switzerland; Groningen, the Netherlands; Oxford, UK; Miami, Florda, USA; Cambridge, UK; and Amsterdam, the Netherlands. Data showed that social anxiety disorder, compared with other anxiety disorders, predicted poorer response and remission to CBT over and above comorbid mood disorders.[54]

Attention Bias Modification Training

Attention bias modification training (ABMT) is a promising alternative approach that may be effective in reducing anxiety in children and adolescents who do not improve with CBT. ABMT consists of a computer-based attention training program in which the person is trained to induce an attentional bias away from threat.[55]

ABMT has been shown to be more effective than placebo for reducing symptoms of anxiety in children and adolescents.[56]

Positive Cognitive Bias Modification for Interpretation

Cognitive bias modification of interpretations (CBM-I) training is an alternative method to reduce anxiety in children and adolescents who do not respond to either CBT or ABMT. CMB-I refers to computerized training to interpret ambiguity in a benign way so as to reduce threat-related interpretations and increase benign interpretations of ambiguous situations in participants' everyday lives. The goal of treatment for individuals with a prior interpretation bias includes training away negative social interpretation bias to reduce social anxiety symptoms. CMB-I has been proven to be more effective than placebo in laboratory studies for school-aged children.[57]

CMB-I has also been shown to be effective for adolescents.[58, 59]


Surgical Care

Surgical consultation for children with infantile facial hemangiomas could potentially prevent development of social anxiety disorder.[60]



Toddlers and young children with excessive shyness and an inhibited temperament in childhood may be at greater risk of social phobia in adolescence. This may be in part related to the caregiver/parent’s response to the child’s emotional reaction to social situations, hence the importance of modeling and encouraging the young child’s ability to ignore negative internal cues and a gradual approach to coping with fears.[31, 32]

Because very low weight (600-1250 g) premature babies may also be at an even higher risk for later development of social anxiety disorder, caregivers/parents should be aware that typical parenting behaviors such as overprotectiveness may further increase risk for the development of social anxiety disorder.[9]

Surgical treatment of infantile facial hemangiomas (IH) may prevent the later development of social anxiety disorder. One study found that preteen children with involuted, untreated facial IHs had greater symptoms of social anxiety compared with children who received treatment for facial IH.[60]


Long-Term Monitoring

Social phobia often leads to extreme social isolation in children and can be accompanied by selective mutism and/or can be a precursor to depression. Intermittent explosive disorder (IED) can also co-occur with social phobia. Data from the National Comorbidity Survey Replication and Adolescent Supplement Study indicated lifetime presence of an anxiety disorder increased the rate of IED by almost 3-fold (7.8% in adolescents without anxiety compared with 22.9% in adolescents with anxiety).[13]  Thus, monitoring for severe anger outbursts may prevent significant morbidity.

Contributor Information and Disclosures

Bettina E Bernstein, DO Distinguished Fellow, American Academy of Child and Adolescent Psychiatry; Distinguished Fellow, American Psychiatric Association; Clinical Assistant Professor of Neurosciences and Psychiatry, Philadelphia College of Osteopathic Medicine; Clinical Affiliate Medical Staff, Department of Child and Adolescent Psychiatry, Children's Hospital of Philadelphia; Consultant to theVillage, Private Practice; Consultant PMHCC/CBH at Family Court, Philadelphia

Bettina E Bernstein, DO is a member of the following medical societies: American Academy of Child and Adolescent Psychiatry, American Psychiatric Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Eduardo Dunayevich, MD Executive Director, Clinical Development, Amgen

Eduardo Dunayevich, MD is a member of the following medical societies: Schizophrenia International Research Society

Disclosure: Received salary from Amgen for employment; Received stock from Amgen for employment.

Additional Contributors

Mohammed A Memon, MD Chairman and Attending Geriatric Psychiatrist, Department of Psychiatry, Spartanburg Regional Medical Center

Mohammed A Memon, MD is a member of the following medical societies: American Association for Geriatric Psychiatry, American Medical Association, American Psychiatric Association

Disclosure: Nothing to disclose.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous coauthor, Kiki D Chang, MD, to the development and writing of this article.

  1. Beidel DC. Social anxiety disorder: etiology and early clinical presentation. J Clin Psychiatry. 1998. 59 Suppl 17:27-32. [Medline].

  2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994 Jan. 51(1):8-19. [Medline].

  3. Heimberg RG, Stein MB, Hiripi E, Kessler RC. Trends in the prevalence of social phobia in the United States: a synthetic cohort analysis of changes over four decades. Eur Psychiatry. 2000 Feb. 15(1):29-37. [Medline].

  4. Wiltink J, Haselbacher A, Knebel A, Tschan R, Zwerenz R, Michal M, et al. Social Phobia - An Anxiety Disorder Underdiagnosed in Outpatient and Consultation-Liaison Service?. Psychother Psychosom Med Psychol. 2009 May 18. [Medline].

  5. Ranta K, Tuomisto MT, Kaltiala-Heino R, Rantanen P, Marttunen M. Cognition, Imagery and Coping among Adolescents with Social Anxiety and Phobia: Testing the Clark and Wells Model in the Population. Clin Psychol Psychother. 2013 Jan 24. [Medline].

  6. Phan KL, Orlichenko A, Boyd E, Angstadt M, Coccaro EF, Liberzon I, et al. Preliminary evidence of white matter abnormality in the uncinate fasciculus in generalized social anxiety disorder. Biol Psychiatry. 2009 Oct 1. 66(7):691-4. [Medline]. [Full Text].

  7. Stein MB. Neurobiological perspectives on social phobia: from affiliation to zoology. Biol Psychiatry. 1998 Dec 15. 44(12):1277-85. [Medline].

  8. Conner OL, Siegle GJ, McFarland AM, et al. Mom-it helps when you're right here! Attenuation of neural stress markers in anxious youths whose caregivers are present during fMRI. PLoS One. 2012. 7(12):e50680. [Medline]. [Full Text].

  9. Constable RT, Ment LR, Vohr BR, Kesler SR, Fulbright RK, Lacadie C, et al. Prematurely born children demonstrate white matter microstructural differences at 12 years of age, relative to term control subjects: an investigation of group and gender effects. Pediatrics. 2008 Feb. 121(2):306-16. [Medline].

  10. Roberts S, Keers R, Lester KJ, Coleman JR, Breen G,et al. HPA AXIS RELATED GENES AND RESPONSE TO PSYCHOLOGICAL THERAPIES: GENETICS AND EPIGENETICS. Depress Anxiety. 2015 Dec. 32 (12):861-70. [Medline].

  11. Burstein M, He JP, Kattan G, Albano AM, Avenevoli S, Merikangas KR. Social phobia and subtypes in the national comorbidity survey-adolescent supplement: prevalence, correlates, and comorbidity. J Am Acad Child Adolesc Psychiatry. 2011 Sep. 50(9):870-80. [Medline]. [Full Text].

  12. Pöhlmann K, Döbbel S, Löffler S, Israel M, Joraschky P. [Social phobia - the blind spot: infrequently diagnosed, highly complex, and a predictor for unfavourable therapy outcomes?]. Z Psychosom Med Psychother. 2009. 55(2):180-8. [Medline].

  13. Keyes KM, McLaughlin KA, Vo T, Galbraith T, Heimberg RG. ANXIOUS AND AGGRESSIVE: THE CO-OCCURRENCE OF IED WITH ANXIETY DISORDERS. Depress Anxiety. 2015 Sep 30. [Medline].

  14. Fichter MM, Kohlboeck G, Quadflieg N, Wyschkon A, Esser G. From childhood to adult age: 18-year longitudinal results and prediction of the course of mental disorders in the community. Soc Psychiatry Psychiatr Epidemiol. 2009 Sep. 44(9):792-803. [Medline].

  15. Kuusikko S, Pollock-Wurman R, Jussila K, Carter AS, Mattila ML, Ebeling H, et al. Social anxiety in high-functioning children and adolescents with Autism and Asperger syndrome. J Autism Dev Disord. 2008 Oct. 38(9):1697-709. [Medline].

  16. Weinstock LS. Gender differences in the presentation and management of social anxiety disorder. J Clin Psychiatry. 1999. 60 Suppl 9:9-13. [Medline].

  17. Lau AS, Fung J, Wang SW, Kang SM. Explaining elevated social anxiety among Asian Americans: emotional attunement and a cultural double bind. Cultur Divers Ethnic Minor Psychol. 2009 Jan. 15(1):77-85. [Medline].

  18. Hsu L, Alden LE. Cultural influences on willingness to seek treatment for social anxiety in Chinese- and European-heritage students. Cultur Divers Ethnic Minor Psychol. 2008 Jul. 14(3):215-23. [Medline].

  19. Guntheroth W. Link among mitral valve prolapse, anxiety disorders, and inheritance. Am J Cardiol. 2007 May 1. 99(9):1350. [Medline].

  20. Hamilton JL, Potter CM, Olino TM, Abramson LY, Heimberg RG, Alloy LB. The Temporal Sequence of Social Anxiety and Depressive Symptoms Following Interpersonal Stressors During Adolescence. J Abnorm Child Psychol. 2015 Jul 5. [Medline].

  21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision. 4th ed. Washington, DC: American Psychiatric Association; 2000.

  22. Amir N, Beard C, Burns M, Bomyea J. Attention modification program in individuals with generalized anxiety disorder. J Abnorm Psychol. 2009 Feb. 118(1):28-33. [Medline].

  23. Suveg C, Hudson JL, Brewer G, Flannery-Schroeder E, Gosch E, Kendall PC. Cognitive-behavioral therapy for anxiety-disordered youth: secondary outcomes from a randomized clinical trial evaluating child and family modalities. J Anxiety Disord. 2009 Apr. 23(3):341-9. [Medline].

  24. Titov N, Andrews G, Johnston L, Schwencke G, Choi I. Shyness programme: longer term benefits, cost-effectiveness, and acceptability. Aust N Z J Psychiatry. 2009 Jan. 43(1):36-44. [Medline].

  25. Suveg C, Sood E, Comer JS, Kendall PC. Changes in emotion regulation following cognitive-behavioral therapy for anxious youth. J Clin Child Adolesc Psychol. 2009 May. 38(3):390-401. [Medline].

  26. Berger T, Hohl E, Caspar F. Internet-based treatment for social phobia: a randomized controlled trial. J Clin Psychol. 2009 Oct. 65(10):1021-35. [Medline].

  27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013.

  28. Letamendi AM, Chavira DA, Hitchcock CA, Roesch SC, Shipon-Blum E, Stein MB. Selective Mutism Questionnaire: Measurement Structure and Validity. J Am Acad Child Adolesc Psychiatry. 2008 Aug 8. [Medline].

  29. Mazeh D, Bodner E, Weizman R, Delayahu Y, Cholostoy A, Martin T, et al. Co-morbid social phobia in schizophrenia. Int J Soc Psychiatry. 2009 May. 55(3):198-202. [Medline].

  30. Pisano S, Catone G, Pascotto A, Iuliano R, Tiano C, Milone A, et al. Paranoid Thoughts in Adolescents with Social Anxiety Disorder. Child Psychiatry Hum Dev. 2015 Dec 10. [Medline].

  31. Evans KC, Wright CI, Wedig MM, Gold AL, Pollack MH, Rauch SL. A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder. Depress Anxiety. 2008. 25(6):496-505. [Medline].

  32. Stein MB, Goldin PR, Sareen J, Zorrilla LT, Brown GG. Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry. 2002 Nov. 59(11):1027-34. [Medline].

  33. Bögels SM, Perotti EC. Does Father Know Best? A Formal Model of the Paternal Influence on Childhood Social Anxiety. J Child Fam Stud. 2011 Apr. 20(2):171-181. [Medline]. [Full Text].

  34. Maeda F, Nathan JH. Understanding taijin kyofusho through its treatment, Morita therapy. J Psychosom Res. 1999 Jun. 46(6):525-30. [Medline].

  35. van Peer JM, Spinhoven P, van Dijk JG, Roelofs K. Cortisol-induced enhancement of emotional face processing in social phobia depends on symptom severity and motivational context. Biol Psychol. 2009 May. 81(2):123-30. [Medline].

  36. Walter D, Hautmann C, Rizk S, et al. Short term effects of inpatient cognitive behavioral treatment of adolescents with anxious-depressed school absenteeism: an observational study. Eur Child Adolesc Psychiatry. 2010 Nov. 19(11):835-44. [Medline].

  37. Blair K, Shaywitz J, Smith BW, Rhodes R, Geraci M, Jones M, et al. Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry. 2008 Sep. 165(9):1193-202. [Medline].

  38. Duval ER, Javanbakht A, Liberzon I. Neural circuits in anxiety and stress disorders: a focused review. Ther Clin Risk Manag. 2015. 11:115-26. [Medline].

  39. Hauser TU, Iannaccone R, Walitza S, Brandeis D, Brem S. Cognitive flexibility in adolescence: neural and behavioral mechanisms of reward prediction error processing in adaptive decision making during development. Neuroimage. 2015 Jan 1. 104:347-54. [Medline].

  40. Miller G. Society for Neuroscience meeting. Pills and games help conquer fear. Science. 2003 Nov 21. 302(5649):1321. [Medline].

  41. Victor AM, Bernstein GA. Anxiety disorders and posttraumatic stress disorder update. Psychiatr Clin North Am. 2009 Mar. 32(1):57-69. [Medline].

  42. Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us?. J Clin Psychiatry. 2006. 67 Suppl 12:20-6. [Medline].

  43. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995 Sep. 152(9):1368-71. [Medline].

  44. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999 Aug. 19(4):341-8. [Medline].

  45. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008 Mar 15. 63(6):544-9. [Medline].

  46. Rapee RM, Gaston JE, Abbott MJ. Testing the efficacy of theoretically derived improvements in the treatment of social phobia. J Consult Clin Psychol. 2009 Apr. 77(2):317-27. [Medline].

  47. Stangier U, Schramm E, Heidenreich T, Berger M, Clark DM. Cognitive Therapy vs Interpersonal Psychotherapy in Social Anxiety Disorder: A Randomized Controlled Trial. Arch Gen Psychiatry. 2011 Jul. 68(7):692-700. [Medline].

  48. James AC, James G, Cowdrey FA, Soler A, Choke A. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2015 Feb 18. 2:CD004690. [Medline].

  49. Maric M, Heyne DA, de Heus P, van Widenfelt BM, Westenberg PM. The Role of Cognition in School Refusal: An Investigation of Automatic Thoughts and Cognitive Errors. Behav Cogn Psychother. 2011 Jun 29. 1-15. [Medline].

  50. Heyne D, Sauter FM, Van Widenfelt BM, Vermeiren R, Westenberg PM. School refusal and anxiety in adolescence: Non-randomized trial of a developmentally sensitive cognitive behavioral therapy. J Anxiety Disord. 2011 Apr 28. [Medline].

  51. Knijnik DZ, Salum GA Jr, Blanco C, Moraes C, Hauck S, Mombach CK, et al. Defense style changes with the addition of psychodynamic group therapy to clonazepam in social anxiety disorder. J Nerv Ment Dis. 2009 Jul. 197(7):547-51. [Medline].

  52. Midgley N. Re-reading "Little Hans": Freud's case study and the question of competing paradigms in psychoanalysis. J Am Psychoanal Assoc. 2006 Spring. 54(2):537-59. [Medline].

  53. Mörtberg E, Andersson G. Predictors of response to individual and group cognitive behaviour therapy of social phobia. Psychol Psychother. 2013 Jan 18. [Medline].

  54. Hudson JL, Keers R, Roberts S, Coleman JR, Breen G, et al. Clinical Predictors of Response to Cognitive-Behavioral Therapy in Pediatric Anxiety Disorders: The Genes for Treatment (GxT) Study. J Am Acad Child Adolesc Psychiatry. 2015 Jun. 54 (6):454-63. [Medline].

  55. Bechor M, Pettit JW, Silverman WK, Bar-Haim Y, Abend R, Pine DS, et al. Attention Bias Modification Treatment for children with anxiety disorders who do not respond to cognitive behavioral therapy: a case series. J Anxiety Disord. 2014 Mar. 28 (2):154-9. [Medline].

  56. Shechner T, Rimon-Chakir A, Britton JC, Lotan D, Apter A, Bliese PD, et al. Attention bias modification treatment augmenting effects on cognitive behavioral therapy in children with anxiety: randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2014 Jan. 53 (1):61-71. [Medline].

  57. Klein AM, Rapee RM, Hudson JL, Schniering CA, Wuthrich VM, Kangas M, et al. Interpretation modification training reduces social anxiety in clinically anxious children. Behav Res Ther. 2015 Dec. 75:78-84. [Medline].

  58. Fu X, Du Y, Au S, Lau JY. Reducing negative interpretations in adolescents with anxiety disorders: a preliminary study investigating the effects of a single session of cognitive bias modification training. Dev Cogn Neurosci. 2013 Apr. 4:29-37. [Medline].

  59. Reuland MM, Teachman BA. Interpretation bias modification for youth and their parents: a novel treatment for early adolescent social anxiety. J Anxiety Disord. 2014 Dec. 28 (8):851-64. [Medline].

  60. Costa VA, Haimowitz R, Cheng YI, Wang J, Silverman RA, Bauman NM. Social Impact of Facial Infantile Hemangiomas in Preteen Children. JAMA Otolaryngol Head Neck Surg. 2015 Nov 19. 1-7. [Medline].

  61. Bögels SM, Alden L, Beidel DC, et al. Social anxiety disorder: questions and answers for the DSM-V. Depress Anxiety. 2010 Feb. 27(2):168-89. [Medline].

  62. Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol. 1999 Jul. 14(4):239-45. [Medline].

  63. Bailey JE, Papadopoulos A, Lingford-Hughes A, Nutt DJ. D-Cycloserine and performance under different states of anxiety in healthy volunteers. Psychopharmacology (Berl). 2007 Sep. 193(4):579-85. [Medline].

  64. Connor KM, Davidson JR, Potts NL, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol. 1998 Oct. 18(5):373-8. [Medline].

  65. Hofmann SG, Pollack MH, Otto MW. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev. 2006 Fall-Winter. 12(3-4):208-17. [Medline].

  66. Nutt DJ, Bell CJ, Malizia AL. Brain mechanisms of social anxiety disorder. J Clin Psychiatry. 1998. 59 Suppl 17:4-11. [Medline].

  67. Schmidt NB, Richey JA, Buckner JD, Timpano KR. Attention training for generalized social anxiety disorder. J Abnorm Psychol. 2009 Feb. 118(1):5-14. [Medline].

  68. Stallard P, Simpson N, Anderson S, Goddard M. The FRIENDS emotional health prevention programme: 12 month follow-up of a universal UK school based trial. Eur Child Adolesc Psychiatry. 2008 Aug. 17(5):283-9. [Medline].

  69. Stein DJ, Westenberg HG, Yang H, et al. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol. 2003 Dec. 6(4):317-23. [Medline].

  70. Stein MB, Chavira DA. Subtypes of social phobia and comorbidity with depression and other anxiety disorders. J Affect Disord. 1998 Sep. 50 Suppl 1:S11-6. [Medline].

  71. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998 Aug 26. 280(8):708-13. [Medline].

  72. Velosa JF, Riddle MA. Pharmacologic treatment of anxiety disorders in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2000 Jan. 9(1):119-33. [Medline].

  73. Weeks JW, Heimberg RG, Fresco DM, Hart TA, Turk CL, Schneier FR, et al. Empirical validation and psychometric evaluation of the Brief Fear of Negative Evaluation Scale in patients with social anxiety disorder. Psychol Assess. 2005 Jun. 17(2):179-90. [Medline].

  74. Westenberg HG. The nature of social anxiety disorder. J Clin Psychiatry. 1998. 59 Suppl 17:20-6. [Medline].

  75. White M, Dorman SM. Receiving social support online: implications for health education. Health Educ Res. 2001 Dec. 16(6):693-707. [Medline].

  76. Zaider TI, Heimberg RG. Non-pharmacologic treatments for social anxiety disorder. Acta Psychiatr Scand Suppl. 2003. 72-84. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.